Pacific Biosciences of California, Inc.
PACB- Exchange
- Nasdaq
- Industry
- Laboratory Analytical Instruments
- SEC CIK
- 0001299130
In the last 90 days, Pacific Biosciences of California, Inc. insiders filed 0 open-market purchases and 1 sale; 223 institutions reported holding it in 13F filings for Q2 2026, worth $320.8M in total; superinvestors ARK Invest and HHLR Advisors (Hillhouse) hold it.
13F holders, Q4 2023
Institutional positions in Pacific Biosciences of California, Inc. as of Dec 31, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 274
- +3 vs. Q3 2023
- Shares held
- 281.0M
- +20.9M (+8.0%) vs. Q3 2023
- Total value
- $2.76B
- +$573.0M (+26.3%) vs. Q3 2023
- New holders
- 48
- 103 more added
- Sold out
- 45
- 75 more reduced
4 institutions that held it in Q3 2023 haven't filed for Q4 2023 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q3 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting PACB on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 223 | $320.8M |
| Q1 2026 | 231 | $248.5M |
| Q4 2025 | 216 | $373.5M |
| Q3 2025 | 208 | $237.8M |
| Q2 2025 | 207 | $245.8M |
| Q1 2025 | 225 | $265.6M |
| Q4 2024 | 227 | $475.1M |
| Q3 2024 | 226 | $394.3M |
| Q2 2024 | 229 | $331.9M |
| Q1 2024 | 268 | $1.01B |
| Q4 2023 | 274 | $2.76B |
| Q3 2023 | 275 | $2.20B |
| Q2 2023 | 272 | $3.37B |
| Q1 2023 | 260 | $2.93B |
| Q4 2022 | 237 | $1.84B |
| Q3 2022 | 227 | $1.23B |
| Q2 2022 | 230 | $1.03B |
| Q1 2022 | 250 | $2.03B |
| Q4 2021 | 256 | $4.20B |
| Q3 2021 | 246 | $4.83B |
| Q2 2021 | 261 | $6.04B |
| Q1 2021 | 263 | $5.47B |
Institutions, Q4 2023
Shares, value and share of portfolio for each institution holding Pacific Biosciences of California, Inc.; share changes are against Q3 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Allspring Global Investments Holdings, LLC | 0 | $0 | 0.00% | −20,962−100.0% | Sold out |
| Diametric Capital, LP | 0 | $0 | 0.00% | −20,837−100.0% | Sold out |
| Nebula Research & Development LLC | 0 | $0 | 0.00% | −19,596−100.0% | Sold out |
| Water Island Capital LLC | 0 | $0 | 0.00% | −16,000−100.0% | Sold out |
| Ascension Capital Advisors, Inc. | 0 | $0 | 0.00% | −15,800−100.0% | Sold out |
| Counterpoint Mutual Funds LLC | 0 | $0 | 0.00% | −15,615−100.0% | Sold out |
| Bridgefront Capital, LLC | 0 | $0 | 0.00% | −12,905−100.0% | Sold out |
| Cetera Advisor Networks LLC | 0 | $0 | 0.00% | −11,815−100.0% | Sold out |
| Cutler Group LP | 0 | $0 | 0.00% | −10,620−100.0% | Sold out |
| My Legacy Advisors, LLC | 0 | $0 | 0.00% | −10,000−100.0% | Sold out |
| Lazard Asset Management LLC | 0 | $0 | 0.00% | −3,549−100.0% | Sold out |
| Pittenger & Anderson Inc | 0 | $0 | 0.00% | −890−100.0% | Sold out |
| Grove Bank & Trust | 0 | $0 | 0.00% | −233−100.0% | Sold out |
| Creative Planning | 0 | $0 | 0.00% | −200−100.0% | Sold out |
| CarsonAllaria Wealth Management, Ltd. | 0 | $0 | 0.00% | −198−100.0% | Sold out |
| Massmutual Trust Co FSB | 0 | $0 | 0.00% | −66−100.0% | Sold out |
| Parallel Advisors, LLC | 0 | $0 | 0.00% | −46−100.0% | Sold out |
| Federated Hermes, Inc. | 0 | $0 | 0.00% | −19−100.0% | Sold out |
| Crewe Advisors LLC | 0 | $0 | 0.00% | −14−100.0% | Sold out |
| Decheng Capital Management III (Cayman), LLC | – | – | – | – | Not filed |
| Trellus Management Company, LLC | – | – | – | – | Not filed |
| Pathstone Family Office, LLC | – | – | – | – | Not filed |
| Steward Financial Group LLC | – | – | – | – | Not filed |